CClinicalTrials.gg
TerminatedNCT03564795Updated Aug 1, 2024Results posted

Effectiveness of KeraStat Gel for Improved Cosmesis of Partial Thickness Burns

An interventional study of KeraStat Gel and Silver Sulfadiazine in Partial-thickness Burn, sponsored by KeraNetics, LLC. Terminated at 1 site in United States. Open to participants aged 6 Years to 100 Years. Per ClinicalTrials.gov, last updated 2024-08-01.

Sponsored by KeraNetics, LLC · Not applicable, Interventional, and Treatment

Why this study was terminated
Low enrollment
Phase
Not applicable
Study type
Interventional
Enrollment
14
Allocation
Randomized
Ages
6 Years to 100 Years
Sex
All
01

Study summary

A randomized, controlled, 30-subject, within-subject trial for examining the effectiveness of KeraStat Gel, as opposed to the institutional standard of care, silver sulfadiazine, in improving cosmesis of the healed wound.

Read the detailed description

The study seeks to determine whether the use of KeraStat Gel as the primary dressing for partial thickness burns results in improved cosmesis of the healed wound, and results in less painful dressing changes, faster reepithelialization, and reduction in need for excision and grafting. The study will enroll 30 subjects. The study design is a randomized, controlled, within-subject trial to compare the effectiveness of KeraStat Gel vs. standard of care (SOC), silver sulfadiazine (SSD). Each of two distinct burns will be randomized to the use of KeraStat Gel or SOC. Patients will be seen weekly for the first month and then at months 3, 6, and 12 post burn.

02

Conditions studied

  • Partial-thickness Burn

Browse trials for

Keywords

  • Wound Dressing
  • Keratin
  • Hydrogel
  • Burn Dressing
03

In context

Burns

719 studies on the registry are indexed under Burns; 145 are open to participants now.

This study's enrollment of 14 is below the median of 40 across 524 interventional studies indexed under Burns.

Browse Burns studies →

Lead sponsor

KeraNetics, LLC is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Presenting with at least two comparable, discrete, and separate partial thickness thermal burns, as determined by the Investigator, measuring 50 - 1,000 cm2 each
  • Study wounds identified are partial thickness depth
  • KeraStat Gel and SSD can be applied to randomized study burn wounds as definitive care treatment within 24 hours from time of injury]
  • Overall total body surface area burned \< 20%

Exclusion criteria

Exclusion Criteria:

  • Pregnant or nursing
  • Prisoner
  • Presence of inhalation injury, as determined by the Investigator
  • Injury requiring formal intravenous fluid resuscitation
  • Concomitant non-thermal traumatic injuries
  • Chronic medical conditions including, but not limited to, documented renal impairment (Cr > 2.5 mg/dL), hepatic impairment (Total bilirubin > 2.5 mg/dL), thromboembolic disorders, active infection in study wound areas, uncontrolled diabetes (HbA1C > 7%), HIV infection, history of melanoma or systemic malignancy within the last 10 years
  • Receiving corticosteroids, immunosuppressive agents, radiation or chemotherapy, topical growth factors, or any other medication the Investigator feels will affect wound healing
  • Not expected to live at least 13 months post-burn
  • Received an investigational drug or biologic within 3 months prior to injury
  • Previously treated with a skin graft at either of the treatment sites
  • Chemical or electrical burn
  • Known or documented allergy to sulfonamides
  • Proposed study wounds are full thickness
  • Any condition the Investigator determines will compromise subject safety or prevent the subject from completing the study
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    KeraStat Gel

    Each enrolled subject will have at least one eligible burn randomized to the KeraStat Gel arm. This burn will be dressed with KeraStat Gel and covered by a secondary dressing. Subjects will be instructed to change the dressing and re-apply the KeraStat Gel per the instructions for use (at least every 3 days).

    Device: KeraStat Gel

  • Active comparator
    Silver Sulfadiazine

    Each enrolled subject will have at least one eligible burn randomized to the Silver Sulfadiazine arm. This burn will be dressed with the Silver Sulfadiazine and covered by a secondary dressing. Subjects will be instructed to change the dressing and re-apply the Silver Sulfadiazine per the institution's Standard of Care instructions.

    Device: Silver Sulfadiazine

Interventions

  • DeviceKeraStat Gel

    Wound dressing for partial thickness burns

  • DeviceSilver Sulfadiazine

    Wound dressing for partial thickness burns

    Also known as: SSD

06

What researchers measure

Primary outcomes

  1. Improved Cosmesis

    The degree of cosmetic improvement of the healed wound will be assessed by Patient and Observer Scar Assessment Scale (POSAS) at one year. This scale consists of two parts: a Patient Scale and an Observer Scale. Both scales contain six items that are scored numerically on a 10-point range, where a '10' indicates the 'worst possible' \[e.g. itching or pigmentation\] and a '1' indicates normal skin. The Patient Scale is summed to make a 'Total Patient Score" ranging from 6 - 60. The Observer Scale is summed to make up a 'Total Observer Score' ranging from 6 - 60. The Total Patient Score and Total Observer Score can be summed into a Total POSAS Score ranging from 12 to 120.

    Time frame: One year post burn

Secondary outcomes

  1. Pain During Dressing Change

    Subject will complete Visual Analog Pain Scale (VAS) before and after in-clinic dressing changes. The Visual Analog Scale is presented as a 10 cm horizontal line ranging from 'No Pain' (0 cm) to 'Worst Pain Imaginable' (10 cm). The patient will mark the line to represent his or her level of pain before and after dressing changes.

    Time frame: Period during first month when dressing changes are required (Day 0, Day 7, Day 14, Day 21, Day 28).

07

Results

Posted Aug 1, 2024

Participant flow

Participant flow — Overall Study
MilestoneAll Participants
Started14
Kerastat gel-treated:14
Silver sulfadiazine-treated:14
Completed3
Not completed11
Withdrew: Withdrawal by subject3
Withdrew: Lost to follow-up6
Withdrew: Physician decision2

Outcome measures

PrimaryImproved Cosmesis

The degree of cosmetic improvement of the healed wound will be assessed by Patient and Observer Scar Assessment Scale (POSAS) at one year. This scale consists of two parts: a Patient Scale and an Observer Scale. Both scales contain six items that are scored numerically on a 10-point range, where a '10' indicates the 'worst possible' \[e.g. itching or pigmentation\] and a '1' indicates normal skin. The Patient Scale is summed to make a 'Total Patient Score" ranging from 6 - 60. The Observer Scale is summed to make up a 'Total Observer Score' ranging from 6 - 60. The Total Patient Score and Total Observer Score can be summed into a Total POSAS Score ranging from 12 to 120.

Time frame:
One year post burn
Reported as:
Mean · score on a scale
Improved Cosmesis
score on a scaleKeraStat GelSilver Sulfadiazine
POSAS - Observer (3 Month)12 ± 5.8612.125 ± 5.62
POSAS - Observer (6 Month)10 ± 3.2410 ± 2.92
POSAS - Observer (12 Month)7.67 ± 2.896 ± 4.36
POSAS - Patient (3 Month)4.125 ± 2.854.875 ± 2.95
POSAS - Patient (6 Month)5.4 ± 4.345.2 ± 4.09
POSAS - Patient (12 Month)6 ± 4.364.67 ± 3.51
SecondaryPain During Dressing Change

Subject will complete Visual Analog Pain Scale (VAS) before and after in-clinic dressing changes. The Visual Analog Scale is presented as a 10 cm horizontal line ranging from 'No Pain' (0 cm) to 'Worst Pain Imaginable' (10 cm). The patient will mark the line to represent his or her level of pain before and after dressing changes.

Time frame:
Period during first month when dressing changes are required (Day 0, Day 7, Day 14, Day 21, Day 28).
Reported as:
Mean · score on a scale
Pain During Dressing Change
score on a scaleAll Participants
Day 0 - Pain Score Immediately Prior to Dressing Change - KeraStat Gel3.14 ± 3.74
Day 0 - Pain Score Immediately Prior to Dressing Change - SSD2.86 ± 3.39
Day 0 - Pain Score During Dressing Change - KeraStat Gel4.14 ± 3.51
Day 0 - Pain Score During Dressing Change - SSD4.00 ± 3.46
Day 0 - Pain Score Immediately Following Dressing Change - KeraStat Gel4.14 ± 3.68
Day 0 - Pain Score Immediately Following Dressing Change - SSD3.64 ± 3.32
Day 0 - Pain Score 15 Minutes After Dressing Change - KeraStat Gel4.07 ± 3.38
Day 0 - Pain Score 15 Minutes After Dressing Change - SSD3.42 ± 2.93
Day 7 - Pain Score Immediately Prior to Dressing Change - KeraStat Gel2.57 ± 3.55
Day 7 - Pain Score Immediately Prior to Dressing Change - SSD3.00 ± 3.70
Day 7 - Pain Score During Dressing Change - KeraStat Gel3.86 ± 4.34
Day 7 - Pain Score During Dressing Change - SSD4.00 ± 4.32
Day 7 - Pain Score Immediately Following Dressing Change - KeraStat Gel3.29 ± 3.73
Day 7 - Pain Score Immediately Following Dressing Change - SSD3.57 ± 3.95
Day 7 - Pain Score 15 Minutes After Dressing Change - KeraStat Gel2.71 ± 3.09
Day 7 - Pain Score 15 Minutes After Dressing Change - SSD3.00 ± 3.37
Day 14 - Pain Score Immediately Prior to Dressing Change - KeraStat Gel1.80 ± 1.48
Day 14 - Pain Score Immediately Prior to Dressing Change - SSD1.20 ± 1.10
Day 14 - Pain Score During Dressing Change - KeraStat Gel2.00 ± 1.58
Day 14 - Pain Score During Dressing Change - SSD1.40 ± 1.34
Day 14 - Pain Score Immediately Following Dressing Change - KeraStat Gel1.90 ± 1.88
Day 14 - Pain Score Immediately Following Dressing Change - SSD1.50 ± 1.50
Day 14 - Pain Score 15 Minutes After Dressing Change - KeraStat Gel1.70 ± 1.64
Day 14 - Pain Score 15 Minutes After Dressing Change - SSD1.30 ± 1.48
Day 21 - Pain Score Immediately Prior to Dressing Change - KeraStat Gel1.00 ± 1.00
Day 21 - Pain Score Immediately Prior to Dressing Change - SSD0.33 ± 0.58
Day 21 - Pain Score During Dressing Change - KeraStat Gel1.00 ± 1.00
Day 21 - Pain Score During Dressing Change - SSD0.33 ± 0.58
Day 21 - Pain Score Immediately After Dressing Change - KeraStat Gel1.00 ± 1.00
Day 21 - Pain Score Immediately After Dressing Change - SSD0.33 ± 0.58
Day 21 - Pain Score 15 Minutes After Dressing Change - KeraStat Gel1.00 ± 1.00
Day 21 - Pain Score 15 Minutes After Dressing Change - SSD0.33 ± 0.58
Day 28 - Pain Score Immediately Prior to Dressing Change - KeraStat Gel1.00 ± NA
Day 28 - Pain Score Immediately Prior to Dressing Change - SSD1.00 ± NA
Day 28 - Pain Score During Dressing Change - KeraStat Gel1.00 ± NA
Day 28 - Pain Score During Dressing Change - SSD1.00 ± NA
Day 28 - Pain Score Immediately Following Dressing Change - KeraStat Gel1.00 ± NA
Day 28 - Pain Score Immediately Following Dressing Change - SSD1.00 ± NA
Day 28 - Pain Score 15 Minutes After Dressing Change - KeraStat Gel1.00 ± NA
Day 28 - Pain Score 15 Minutes After Dressing Change - SSD1.00 ± NA

Adverse events

Collected over Through study completion, up to 1 year. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
KeraStat Gel-treated Wound0/14 (0%)0/14 (0%)0/14 (0%)
Silver Sulfadiazine-treated Wound0/14 (0%)0/14 (0%)0/14 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)All Participants
<=18 years1
Between 18 and 65 years13
>=65 years0
Age, Continuous
Age, Continuous(years)All Participants
Mean38.07 ± 16.9
Sex: Female, Male
Sex: Female, Male(Participants)All Participants
Female1
Male13
Race (NIH/OMB)
Race (NIH/OMB)(Participants)All Participants
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American3
White11
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)All Participants
United States14
08

Study locations

1 site
  • Wake Forest University Health Sciences
    Winston-Salem, North Carolina 27157, United States
09

References and documents

Publications

  • Wasiak J, Cleland H, Campbell F. Dressings for superficial and partial thickness burns. Cochrane Database Syst Rev. 2008 Oct 8;(4):CD002106. doi: 10.1002/14651858.CD002106.pub3. PubMed 18843629 ↗
  • Tandara AA, Mustoe TA. The role of the epidermis in the control of scarring: evidence for mechanism of action for silicone gel. J Plast Reconstr Aesthet Surg. 2008 Oct;61(10):1219-25. doi: 10.1016/j.bjps.2008.03.022. Epub 2008 Jul 23. PubMed 18653391 ↗
  • Mustoe TA, Gurjala A. The role of the epidermis and the mechanism of action of occlusive dressings in scarring. Wound Repair Regen. 2011 Sep;19 Suppl 1(0 1):s16-21. doi: 10.1111/j.1524-475X.2011.00709.x. PubMed 21793961 ↗
  • Steinstraesser L, Flak E, Witte B, Ring A, Tilkorn D, Hauser J, Langer S, Steinau HU, Al-Benna S. Pressure garment therapy alone and in combination with silicone for the prevention of hypertrophic scarring: randomized controlled trial with intraindividual comparison. Plast Reconstr Surg. 2011 Oct;128(4):306e-313e. doi: 10.1097/PRS.0b013e3182268c69. PubMed 21921743 ↗
  • Bloemen MC, van der Veer WM, Ulrich MM, van Zuijlen PP, Niessen FB, Middelkoop E. Prevention and curative management of hypertrophic scar formation. Burns. 2009 Jun;35(4):463-75. doi: 10.1016/j.burns.2008.07.016. Epub 2008 Oct 31. PubMed 18951704 ↗

Study documents

  • Protocol and statistical analysis plan · Jul 5, 2021

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03564795
Lead sponsor
KeraNetics, LLC
Collaborators
Wake Forest University, United States Department of Defense
Responsible party
Sponsor
First posted
Jun 21, 2018
Start date
Aug 31, 2018
Primary completion
Mar 31, 2023
Completion
Mar 31, 2023
Results posted
Aug 1, 2024
Last update
Aug 1, 2024

Study contacts

James H Holmes IV, MD
principal investigator · Wake Forest Burn Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion